Stocklytics score rationale: value 58, quality 38, growth 0.
Financials
2019
2020
2021
2022
2023
2024
2025
54184000
76657000
313837000
477706000
251455000
227043000
170155000
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence…
Forecast
Consensus Buy from 11 analysts. Average price target $5.00, -63.5% versus the current price. Low $5.00. High $5.00.
Analysts have an average 12-month price target of $5.00 for Ginkgo Bioworks Holdings (DNA), 63.3% below the current price of $13.62. Of 3 analysts covering the stock, 0 rate it Buy or Strong Buy, 1 Hold, and 2 Sell or Strong Sell, giving a consensus of Sell.
Forecasts are third-party estimates and often wrong. They are not investment advice.
DNA price target
12-month price target
Low
$5.00
Average
$5.00
High
$5.00
The average is 63.3% below the current price of $13.62.
Is Ginkgo Bioworks Holdings a buy or sell?
Of 3 analysts, 0 rate Ginkgo Bioworks Holdings Buy or Strong Buy, 1 Hold, and 2 Sell or Strong Sell. The consensus label is Sell. That split is not a recommendation.
Ginkgo Bioworks Holdings earnings and revenue forecast
The Stocklytics Score for DNA is 32 out of 100. It averages value, quality, and growth against a large-cap US universe. It is not a price target and not a buy or sell rating. Fair value is a separate estimate on the fair value tab.
DNA forecast FAQs
What is the DNA price target?
$5.00 average, with a published range of $5.00 to $5.00.
Is Ginkgo Bioworks Holdings a buy or sell?
The consensus is Sell from 3 analysts. This is not a recommendation.
What is the Ginkgo Bioworks Holdings stock forecast for 2026?
Analysts' average EPS estimate for 2026 on file is -3.91. The average revenue estimate is $85.07 million.
What will DNA be worth in 2030?
No reliable forecast exists that far out.
When is Ginkgo Bioworks Holdings's next earnings report?
The next earnings date is shown on the stock page when a future report is on the calendar. This forecast does not invent a date.
Capital is at risk. Stocklytics is operated by Stocklytics Inc., a Marshall Islands company. It is not regulated by the FCA and does not give investment advice.